Item 1.01. Entry into a Material Definitive Agreement.
On
Under the Original Agreement, the Company granted CANbridge (a) a license to
certain intellectual property rights, including those relating to sL65, the
first capsid produced from the Company's sAAVyTM platform, for the development
and commercialization of gene therapy candidates for the treatment of Fabry and
Pompe diseases (the "Fabry and Pompe License"), (b) options to license certain
intellectual property rights, including those relating to sL65, for the
development and commercialization of gene therapy candidates for two additional
indications (the "Candidate Options"), and (c) an option to obtain a license to
develop and commercialize LB-001 for the treatment of methylmalonic acidemia in
Under the A&R Agreement, the Candidate Options and the LB-001 Option are removed
as mutually agreed by both parties. Further, in connection with the Fabry and
Pompe License, the A&R Agreement grants CANbridge a non-exclusive license to
certain Company intellectual property rights related to manufacturing for the
Fabry and Pompe programs. Additionally, under the A&R Agreement, the research
plan has been amended to reflect that the full transfer of the technology
pertaining to the Fabry and Pompe programs to CANbridge will be effective as of,
Under the Original Agreement, the Company was eligible to receive clinical,
regulatory and commercial milestone payments of up to
The Original Agreement included certain automatic product reversion terms, in the event of a termination of the agreement, under certain circumstances. Under the A&R Agreement, LogicBio and CANbridge will negotiate a product reversion agreement in good faith in the event of a termination of the A&R Agreement under certain circumstances.
The foregoing summary of the A&R Agreement does not purport to be complete and
is subject to, and qualified in its entirety by, the full text of the Agreement,
a copy of.which the Company plans to file, with confidential terms redacted,
with the
--------------------------------------------------------------------------------
© Edgar Online, source